Filing Flows › Voyager Therapeutics (VYGR) › Q3 2026 › vs Q2 2026
Voyager Therapeutics (VYGR) Q3 2026 vs Q2 2026 (quarter over quarter)
Voyager Therapeutics's revenue rose $849K (+27%) from $3.2M in Q2 2026 to $4.0M in Q3 2026.
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $4.0M | $3.2M | $849K | +27% |
| Other income, net | $1.7M | $1.9M | −$193K | -10% |
| Net loss | $24.7M | $24.5M | $221K | +0.9% |
| Costs & expenses | $30.5M | $29.6M | $877K | +3% |
| Operating costs | $30.4M | $29.6M | $879K | +3% |
| Income tax | $18K | $20K | −$2K | -10% |
| Research & development | $24.4M | $22.0M | $2.3M | +11% |
| General & admin | $6.1M | $7.5M | −$1.5M | -19% |
| Operating cash sources | $24.7M | $24.5M | $221K | +0.9% |
| Depreciation | $836K | $908K | −$72K | -8% |
| Share-based compensation | $2.6M | $2.4M | $170K | +7% |
| Working capital & other | $1.6M | −$4.7M | $6.3M | — |
| Cash used in operations | $19.7M | $25.8M | −$6.2M | -24% |
| Net loss absorbed | $24.7M | $24.5M | $221K | +0.9% |
Questions
How much did Voyager Therapeutics's revenue grow quarter over quarter in Q3 2026?
Voyager Therapeutics's revenue rose $849K (+27%) from $3.2M in Q2 2026 to $4.0M in Q3 2026.